your market intelligence analyst
Search Results
660 results
Your search is now limited to «Company Strategy» expert search.
BioPharma Dive 07/19/2019 11:35
Roche's Genentech unit filed motions on July 10 for a temporary restraining order and a preliminary injunction against Amgen.
More from BioPharma Dive:
FiercePharmaManufacturing 07/19/2019 11:27
When we can come in and talk about Pfizer oncology and the broad portfolio of medicines that could have utility for patients, that enables a different conversation with cancer centers, with health plans, with reimbursement authorities,” Schmeltz pointed out.
More from FiercePharmaManufacturing:
PharmaManufacturing 07/19/2019 11:20
Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States.
More from PharmaManufacturing:
PR Newswire 07/19/2019 07:19
It is estimated that the release of AbbVie's JAK will have an immediate impact on the RA treatment landscape and could capture a significant amount of share within the first six months of launch.
More from PR Newswire:
Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases.
More from Middle East North Africa Financial Network (MENAFN):
Seeking Alpha 07/18/2019 10:21
Once the FTC accepts the consent order and the other customary closing conditions are satisfied, Bristol-Myers Squibb intends to close the Celgene transaction at the earliest possible date, which it currently expects to be at the end of 2019 or the beginning of 2020.
More from Seeking Alpha:
GlobeNewswire 07/18/2019 08:30
The companies discontinued that agreement in conjunction with the end of the Research term of the collaboration in December 2018 and the collaboration agreement with Sanofi concluded in its entirety on April 1, 2019.
More from GlobeNewswire:
NGT News 07/17/2019 13:19
Recognizing the link between a healthy environment and human health, we believe that by investing in electric vehicles and emissions-reduction initiatives, we can help reduce the burden of respiratory diseases and other air pollution-related conditions,” says Katarina Ageborg, executive vice president of sustainability and chief compliance officer at AstraZeneca ...
STING pathway signaling plays an important role in the generation of an immune response directed at tumors, and enhancing STING signaling has shown promise in a variety of. .
More from Pharmaceutical Business Review:
Business Insider 07/16/2019 16:06
Read more: Pharma giants like Novartis and Sanofi are betting that the future of healthcare looks more like an app or sensor than a prescription So in addition to selling traditional medications like insulin for individuals with diabetes, Sanofi is now also investing in digital offerings ...
More from Business Insider:
3BL Media 07/16/2019 08:10
Merck partnered with INROADS, an international nonprofit organization that prepares talented, diverse youth for corporate and community leadership, to launch College Links in Newark, New Jersey earlier this year.
More from 3BL Media:
ETHealthWorld (India) 07/16/2019 04:10
AbbVie's Humira, used to treat rheumatoid arthritis and spondylitis, racked up nearly $20 billion in sales in 2018, while Amgen and Pfizer 's Enbrel still brings in $7 billion annually after 20 years on the market.
More from ETHealthWorld (India):
PMLiVE 07/15/2019 19:19
AbbVie is still in the throes of the biggest acquisition in its history – the $63bn takeover of Allergan – but clearly still has aspirations to do bolt-on deals to boost its pipeline.
More from PMLiVE:
Becker's Hospital Review 07/15/2019 16:36
The newspaper states that the agreement — which restricts Gilead's ability to acquire Galapagos or increase its stake in the Belgian company beyond 29.9 percent — could also help Galapagos keep its independence.
More from Becker's Hospital Review:
Investor's Business Daily 07/15/2019 16:20
But they acknowledged Gilead could still make an acquisition in 2019.
More from Investor's Business Daily: 07/15/2019 11:33
To concentrate on the strategy, GSK had sold 10 tail-end brands in FY19, including its Vitamin C brand Celin and anti-infective brand Septran.
More from

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications